Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to knock out genes with one dose. Intellia’s partnerships have fueled its pipeline: a 2016 deal with Regeneron co-developed NTLA-2001 ts2.tech, and Regeneron later expanded the alliance to other targets. Other collaborations include AvenCell, Kyverna, ONK Therapeutics and ReCode, which use Intellia’s platform to engineer cell therapies or improve delivery ts2.tech. These alliances help the small company leverage resources while concentrating on its late-stage in-vivo programs. Recent restructuring and discontinuation of a Phase 1 program reflect Intellia’s narrow focus on ATTR and HAE ts2.tech.
9 October 2025
··
Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s capital Tashkent buzzed with business activity as the country opened the First International Uzbek Import Fair 2025. The exhibition, held at the Uzexpocentre on October 7–9, is a cornerstone of President Shavkat Mirziyoyev’s industrial strategy to boost local production. Deputy PM Jamshid Khodjaev, inaugurating the fair, emphasized its mission to deepen industrial cooperation, support domestic manufacturers, and promote import substitution uzdaily.uz. The theme “Optimizing Imports and Increasing Local Content” underscores a shift in policy: instead of curbing imports via tariffs or bans, Uzbekistan wants to partner with foreign firms to produce imported goods locally euronews.com.
9 October 2025
·
United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

As of market close Oct 8, 2025, UAL traded around $98.09 reuters.com, a ~1.5% gain for the day. In early pre-market Oct 9, it had jumped ~6% to ~$104 stockanalysis.com. Over the past week, UAL shares have rebounded from recent lows near ~$94 to fresh highs around $99–100. The stock’s 6-month chart shows a rally to a mid-September peak followed by a pullback; current technical indicators suggest mild momentum. UAL trades well above its pandemic lows and has outperformed some broader indices this year.
9 October 2025
··
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com.
9 October 2025
··
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago ts2.tech. Such dramatic swings are not unusual for a pre-revenue biotech stock – especially one at the intersection of two hot themes that can amplify volatility.
9 October 2025
···
American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

American Airlines’ stock has been on a turbulent ride in 2025. After starting the year in the high teens, AAL has sunk into the low double-digits – recently closing around $11.81 marketbeat.com. The slide accelerated in September amid soft travel demand and pessimistic guidance. As of early October, shares were down over 34% year-to-date and about 15% lower in the past month alone marketbeat.com. This steep drop reflects both company-specific challenges and broader sector headwinds.
9 October 2025
··
Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Serve Robotics grabbed headlines this week with a major new partnership announcement. On October 9, 2025, the company revealed a deal with DoorDash to deploy Serve’s sidewalk delivery robots for food orders on the DoorDash platform investing.com. Initially rolling out in Los Angeles, the pilot means DoorDash customers from select restaurants may have their meals delivered by a Serve robot investing.com. This is a strategic expansion beyond Serve’s exclusive relationship with Uber Eats to date. “This partnership enables us to go to cities where DoorDash is the dominant player… we’re looking for more demand, so that every minute of every day, the robots have access to more jobs,” said Serve co-founder and CEO Ali Kashani, highlighting how tapping DoorDash’s vast user base can boost robot utilization investing.com. The news was met with investor excitement – SERV stock surged about 15% in trading after the announcement investing.com, as the market cheered Serve’s access to DoorDash’s enormous network of merchants and customers.
9 October 2025
··
Gold Hits $4,000 Record, Silver Soars to $50 – Rally to Continue or Crash Ahead?

Gold Hits $4,000 Record, Silver Soars to $50 – Rally to Continue or Crash Ahead?

Gold and silver have been on a record-breaking tear in 2025. Gold entered the year around $2,800 and by October blasted past the $4,000/oz milestone – an unprecedented level ts2.tech ts2.tech. On October 7–8, spot gold surged to an all-time high near $4,078 before settling around $4,038 by Oct. 9 ts2.tech reuters.com. This ~53% year-to-date jump is gold’s steepest annual gain since 1979 reuters.com, vastly outpacing equities ts2.tech. “$4,000 an ounce seemed far-fetched at the start of the year… but after a ~50% rally, here we are,” noted one investment analyst, reflecting widespread amazement at gold’s ascent ts2.tech.
9 October 2025
·
Jefferies Scrambles as First Brands’ $10 Billion Bankruptcy Reveals $2.3 Billion in ‘Vanished’ Debt

Jefferies Scrambles as First Brands’ $10 Billion Bankruptcy Reveals $2.3 Billion in ‘Vanished’ Debt

First Brands Group’s journey from industry consolidator to bankruptcy cautionary tale was swift and dramatic. The company – a leading supplier of replacement auto parts like oil filters, brake pads and windshield wipers – grew aggressively through debt-financed acquisitions in the 2010s Livemint. By 2025, it owned well-known aftermarket brands such as Raybestos, TRICO and FRAM, selling through major retailers like Walmart and AutoZone ts2.tech. However, this rapid expansion came at the cost of a towering debt load that far outpaced its earnings.
9 October 2025
···
Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Wall Street’s momentum in 2025 is undeniable – and increasingly historic. Stocks have been on a tear, repeatedly smashing records. After seven consecutive daily gains to start October, the market took only a brief pause before charging higher again. On October 8, the S&P 500 and Nasdaq Composite clinched fresh all-time highs ts2.tech. These milestones extend what has already been a remarkable year; the S&P is up roughly 18% year-to-date, with the Nasdaq not far behind ts2.tech. Even the blue-chip Dow Jones Industrial Average, while slightly lagging, is near its peak. To put the rally in perspective, the broad market has tacked on roughly $7 trillion in value this year amid this risk-on fervor.
9 October 2025
·····
Nvidia’s $2B Bet on Reflection AI Shakes Up the Global AI Race

Nvidia’s $2B Bet on Reflection AI Shakes Up the Global AI Race

It’s official: Reflection AI has secured one of the largest funding rounds ever for a young tech startup – $2 billion in fresh capital led by Nvidia techmeme.com. The New York Times first reported the blockbuster raise, valuing the one-year-old company at roughly $8 billion techmeme.com. To put that in perspective, Reflection was valued at only ~$545 million as recently as March techmeme.com. In other words, its paper valuation has leapt nearly 15× in just six months, a virtually unheard-of jump. The NYT called this “the latest sign of investor fervor” around AI, even as some worry the boom may be overheating techmeme.com.
9 October 2025
···
Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed, Inc. has seen a stunning reversal in fortune. As of October 9, 2025, the stock trades around $30.36 per share, giving the company a market capitalization of roughly $0.7–0.8 billion reuters.com companiesmarketcap.com. Just weeks ago, Wolfspeed emerged from Chapter 11 bankruptcy after cutting its debt by ~70% and interest costs by ~60% ts2.tech. This financial restructuring wiped out most of the old equity – existing shareholders were left with only ~3–5% of the reorganized company ts2.tech – but set the stage for a dramatic stock rally. In fact, WOLF exploded over 1,000% intraday on September 29, 2025 and continued to jump ~33% on September 30 to a new 52-week high near $32 ts2.tech ts2.tech. New CEO Robert Feurle declared the completion of bankruptcy as “the beginning of a new era”, saying Wolfspeed is “well positioned to capture rising demand” in fast-growing markets like EVs and AI reuters.com. While bulls point to Wolfspeed’s strengthened balance sheet and leadership in silicon carbide semiconductors, analysts remain cautious – the stock is rated a Hold on average, with consensus 12-month price targets around only $8–10 ts2.tech stockanalysis.com. Below, we dive into the latest stock price, recent news and developments, expert commentary, forecasts for
9 October 2025
·
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells Adaptimmune. Adaptimmune’s proprietary platform, known as SPEAR T-cells, allows it to design TCRs that recognize tumor-specific antigens and arm patient T-cells with these receptors ts2.tech ts2.tech. In effect, it’s analogous to CAR-T immunotherapy but applied to solid tumors, a far tougher environment due to tumor defenses and heterogeneity ts2.tech.
9 October 2025
Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

In early October 2025, Ferrari N.V. held a high-profile Capital Markets Day in Maranello, unveiling its 2030 strategic plan and updated guidance. The event proved dramatic – Ferrari’s stock plunged nearly 12% in its worst single-day drop since the company’s 2015 IPO reuters.com. Shares were briefly halted after sliding by double-digits on October 9 reuters.com, and ultimately closed the day deep in the red. This sell-off was sparked by a mix of surprising strategic pivots and cautious long-term targets that rattled some investors, despite Ferrari simultaneously raising near-term forecasts.
9 October 2025
··
Ethereum $5,000 Soon? Fed Cuts, Small-Cap Rally & Whale Moves Fuel Bold Forecasts

Ethereum $5,000 Soon? Fed Cuts, Small-Cap Rally & Whale Moves Fuel Bold Forecasts

Ethereum’s price is once again flirting with record territory after a volatile few weeks. The world’s second-largest crypto came within ~$200 of its all-time high in early October decrypt.co. In late August, ETH actually set a new peak around $4,946 – finally eclipsing its 2021 high – before a sharp September correction decrypt.co. By September 25, Ethereum had plunged below $4,000 amid a broader crypto slump ts2.tech. This pullback rattled some investors but proved short-lived. By early October, ETH regained momentum, climbing back into the mid-$4,000s.
9 October 2025
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray Brands kicked off its fiscal 2026 with better-than-expected results, signaling that aggressive cost-cutting and diversification efforts are bearing fruit. The company’s Q1 FY2026 revenue hit $209.5 million, a 5% increase over last year’s quarter stocktitan.net. More impressively, Tilray managed to swing to a net profit of $1.5 million – a stark improvement from the -$34.7 million loss in the prior-year period stocktitan.net stocktitan.net. This marks one of Tilray’s first profitable quarters since its 2018 IPO, a milestone achieved through tighter operational discipline. Adjusted EBITDA came in at $10.2 million, indicating improving core profitability stocktitan.net.
9 October 2025
··
Delta’s Profits Take Off as Travel Demand Soars – Airline Signals Record Holiday Season Ahead

Delta’s Profits Take Off as Travel Demand Soars – Airline Signals Record Holiday Season Ahead

Delta Air Lines kicked off airline earnings season with a strong September-quarter performance that blew past projections. The carrier earned $1.42 billion in net income for Q3 2025 – almost 60% higher than the year-ago period – translating to $2.17 per share marketscreener.com. Excluding one-time items, Delta’s profit was $1.71 per share, comfortably above the ~$1.52 analysts expected marketscreener.com. Revenue for the quarter reached $16.67 billion, beating forecasts and marking a ~8% increase year-on-year marketscreener.com. These results came in at the top end of management’s guidance, as Delta benefited from robust travel demand over the summer and strong operational execution. “We delivered September quarter results at the top end of our expectations on a combination of strong execution and improving fundamentals,” said CEO Ed Bastian news.delta.com. The airline achieved a healthy operating margin near 10% this quarter news.delta.com, a notable feat given rising labor and fuel costs industry-wide.
9 October 2025
·
Jamie Dimon’s Dire Warning: “Serious” Stock Market Correction Could Hit Soon

Jamie Dimon’s Dire Warning: “Serious” Stock Market Correction Could Hit Soon

Jamie Dimon – one of Wall Street’s most influential bankers – is ringing alarm bells about the soaring U.S. stock market. In an interview with the BBC, the JPMorgan CEO warned that U.S. equities could suffer a major correction within 6 months to 2 years reuters.com. “I am far more worried about that than others,” Dimon admitted, making clear he sees a greater risk of a significant pullback than the average investor right now reuters.com. According to Reuters, he even pegged the odds of a substantial downturn at roughly 30% finviz.com – a striking statement from the long-time banking chief.
9 October 2025
·
PepsiCo’s Sneaky Q3 Beat: Earnings Up, New CFO In, But U.S. Snack Sales Slump – What It Means

PepsiCo’s Sneaky Q3 Beat: Earnings Up, New CFO In, But U.S. Snack Sales Slump – What It Means

PepsiCo’s third-quarter results delivered a mixed bag. On the headline numbers, the snack and beverage giant slightly beat Wall Street expectations – a welcome surprise given tempered forecasts. Core earnings per share of $2.29 edged past consensus, and net revenue of $23.9 billion marked modest growth seekingalpha.com. The company managed this top-line increase despite flat to declining volumes, thanks largely to higher pricing and strength outside the U.S. “Our reported net revenue growth accelerated and reflects the resilience of our international business [and] improved momentum within North America Beverages,” CEO Ramon Laguarta noted investors.pepsico.com. In fact, the PepsiCo Beverages North America unit eked out 2% organic sales growth in Q3 despite lower soda volumes, as brands like Pepsi Zero Sugar and Gatorade benefited from marketing pushes and new formulations.
9 October 2025
·
UiPath Stock Skyrockets on ‘Agentic AI’ Boom – AI Deals & Earnings Fuel Rally

UiPath Stock Skyrockets on ‘Agentic AI’ Boom – AI Deals & Earnings Fuel Rally

UiPath built its name in Robotic Process Automation by automating repetitive, rule-based tasks. Now it’s pivoting toward what it calls “agentic automation,” where AI-powered “agents” handle more complex, knowledge-driven workflows with minimal human input trefis.com. In practical terms, this means going beyond scripted bots: AI agents can understand context, make decisions, and adapt on the fly – a natural evolution in the era of generative AI.
9 October 2025
··
1 … 112 113 114 115 116 … 164

Stock Market Today

  • Revolution Medicines (RVMD) Shares Trade at a Premium Despite Robust Gains
    July 25, 2026, 2:47 PM EDT. Revolution Medicines (RVMD) shares have jumped with a 399.2% return over the past year and approximately 6.4x growth in three years, though the stock's valuation is considered steep. With a P/B ratio of 26.8x, Revolution Medicines is well above the Biotech sector's 2.5x average and peer level of 10.3x. The stock meets just 2 out of 6 valuation criteria, indicating a premium linked to its FDA-reviewed drug daraxonrasib and data from its pancreatic cancer trial, along with concerns tied to regulatory risk.